Arrowhead Pharmaceuticals' Redemplo Receives Positive EMA Recommendation
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy ARWR?
Source: stocktwits
- EMA Recommendation: Arrowhead Pharmaceuticals' Redemplo received a positive opinion from the European Medicines Agency (EMA) Committee, recommending approval for familial chylomicronemia syndrome, with a final decision from the European Commission expected by Q2 2026, potentially opening new market opportunities for the company.
- Wall Street Optimism: Morgan Stanley upgraded Arrowhead from ‘Equal Weight’ to ‘Overweight’ with a price target increase from $78 to $100, reflecting optimism ahead of late-stage Severe Hypertriglyceridemia (sHTG) data, which is expected to unlock a multibillion-dollar market opportunity.
- Analyst Support: According to Koyfin, 10 out of 12 analysts rated Arrowhead as ‘Buy’ or higher, indicating strong market confidence in its future performance, with an average price target of $84.18, representing a potential upside of 14%.
- Retail Trader Sentiment: On Stocktwits, retail sentiment around ARWR stock surged from ‘bullish’ to ‘extremely bullish’ in the past 24 hours, reflecting investor optimism for the impending drug approval in Europe, with the stock rallying approximately 454% over the past 12 months.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ARWR?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ARWR
Wall Street analysts forecast ARWR stock price to rise
11 Analyst Rating
8 Buy
3 Hold
0 Sell
Moderate Buy
Current: 74.400
Low
35.00
Averages
82.00
High
110.00
Current: 74.400
Low
35.00
Averages
82.00
High
110.00
About ARWR
Arrowhead Pharmaceuticals, Inc. develops medicines that treat intractable diseases by silencing the genes that cause them. The Company's therapies, using a broad portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, trigger the RNA interference (RNAi) mechanism to induce rapid, deep and durable knockdown of target genes. The Company's Targeted RNAi Molecule (TRiMTM) platform utilizes ligand-mediated delivery and is designed to enable tissue-specific targeting while being structurally simple. It is focused on various therapeutic areas, such as cardiometabolic, pulmonary, liver, muscle and central nervous system. It has around 16 clinical-stage investigational medicines (wholly owned and partnered), which range in development stage from Phase I to Phase III. The Company's pipeline products include Plozasiran, Zodasiran, Olpasiran, ARO-RAGE, ARO-MMP7, GSK-4532990, Fazirsiran, GSK5637608, ARO-CFB, ARO-INHBE, ARO-C3, ARO-PNPLA3, ARO-DUX4, ARO-DM1 and ARO-ATXN2.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Arrowhead Pharmaceuticals' Redemplo Receives Positive EMA Recommendation
- EMA Recommendation: Arrowhead Pharmaceuticals' Redemplo received a positive opinion from the European Medicines Agency (EMA) Committee, recommending approval for familial chylomicronemia syndrome, with a final decision from the European Commission expected by Q2 2026, potentially opening new market opportunities for the company.
- Wall Street Optimism: Morgan Stanley upgraded Arrowhead from ‘Equal Weight’ to ‘Overweight’ with a price target increase from $78 to $100, reflecting optimism ahead of late-stage Severe Hypertriglyceridemia (sHTG) data, which is expected to unlock a multibillion-dollar market opportunity.
- Analyst Support: According to Koyfin, 10 out of 12 analysts rated Arrowhead as ‘Buy’ or higher, indicating strong market confidence in its future performance, with an average price target of $84.18, representing a potential upside of 14%.
- Retail Trader Sentiment: On Stocktwits, retail sentiment around ARWR stock surged from ‘bullish’ to ‘extremely bullish’ in the past 24 hours, reflecting investor optimism for the impending drug approval in Europe, with the stock rallying approximately 454% over the past 12 months.
See More
US Stocks Rise on Strong Retail Sales and Earnings Reports
- Strong Retail Sales: US March retail sales rose 1.7% month-over-month, exceeding expectations of 1.4% and marking the largest increase in a year, indicating robust consumer spending that could bolster economic recovery and market confidence.
- Earnings Support: UnitedHealth Group (UNH) reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, raising its full-year forecast to above $18.25, which has driven health insurance stocks higher and reflects industry resilience.
- Fed Nomination in Focus: Kevin Warsh's confirmation hearing before the Senate Banking Committee is drawing attention; despite facing an investigation hurdle, Warsh's commitment to an independent Fed and prioritizing inflation control could influence future monetary policy directions.
- International Tensions Impact Oil Prices: WTI crude oil prices fell over 1% as Iran is set to attend peace talks with the US, while the closure of the Strait of Hormuz threatens to exacerbate the global energy crisis, affecting market sentiment.
See More
U.S. Stocks Mixed as Oil Prices Rebound
- Market Performance: The S&P 500 Index fell by 0.13%, and the Dow Jones Industrial Average also declined by 0.13%, while the Nasdaq 100 saw a slight increase of 0.02%, reflecting market volatility influenced by oil price rebounds and economic data.
- Strong Economic Data: March retail sales rose by 1.7% month-over-month, exceeding expectations of 1.4%, marking the largest increase in a year, indicating robust consumer spending that may support stock prices.
- Oil Price Recovery: WTI crude oil prices rebounded by over 2% as market speculation intensified regarding Iran's participation in upcoming peace talks, potentially exacerbating the global energy crisis.
- Impressive Earnings Reports: UnitedHealth Group reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, leading to a stock price increase of over 7% and raising its full-year earnings forecast, showcasing strong performance in the health insurance sector.
See More
US Stocks Close Lower as Oil Prices Rebound Impact Market
- Market Decline: The S&P 500 index fell by 0.63%, the Dow Jones Industrial Average dropped by 0.59%, and the Nasdaq 100 index decreased by 0.42%, reflecting investor concerns over the uncertainty surrounding Iran's geopolitical situation, which dampened market sentiment.
- Oil Price Rebound Impact: WTI crude oil prices rebounded by over 2% after Iran announced it would not attend peace talks, raising fears of a deepening global energy crisis, which could further hinder economic recovery.
- Supportive Economic Data: March retail sales rose by 1.7% month-over-month, surpassing expectations of 1.4%, indicating robust consumer spending that may provide some support for the stock market, despite overall market pressures.
- Fed Nominee Supports Independence: Fed Chair nominee Kevin Warsh emphasized the importance of monetary policy independence and controlling inflation in his Senate Banking Committee statement, which could positively influence market confidence.
See More
Morgan Stanley Upgrades Arrowhead to Overweight with $100 Target
- Rating Upgrade: Morgan Stanley upgraded Arrowhead Pharmaceuticals (ARWR) from Equal Weight to Overweight and raised its price target from $78 to $100, reflecting expectations of significant catalysts over the next 12 months.
- Clinical Trial Catalyst: Analyst Michael Ulz highlighted that data expected in Q3 2026 from the SHASTA 3 and 4 trials will serve as an important catalyst for Arrowhead, particularly for its lead asset plozasiran targeting severe hypertriglyceridemia.
- Sales Forecast Increase: Ulz anticipates that plozasiran will generate $3.2 billion in adjusted peak sales in severe hypertriglyceridemia, significantly up from his prior forecast of $1.7 billion, indicating strong market confidence in the product.
- Future Catalysts: Over the next 12 months, Arrowhead is also set to release initial results for its Alzheimer’s candidate ARO-MAPT and hyperlipidemia candidate ARO-DIMER-PA, further enhancing investor expectations for its pipeline.
See More
Arrowhead Pharmaceuticals Stock Outlook Optimistic
- Clinical Trial Data Release: Arrowhead Pharmaceuticals is set to release phase three clinical trial data for its RNA interference therapeutic Plozasiran, aimed at treating severe hypertriglyceridemia, in Q3 2026, which is expected to drive stock price increases as the market opportunity remains underappreciated.
- Analyst Rating Upgrade: Morgan Stanley upgraded Arrowhead's stock rating from equal weight to overweight and raised its price target from $78 to $100, implying a 44.4% upside from Monday's close, reflecting strong confidence in the company's future performance.
- Strong Stock Performance: Arrowhead's stock has surged over 473% in the past year, indicating robust market demand for its products and investor confidence, with analysts believing this momentum will continue.
- Market Consensus Support: Among the 13 analysts covering the stock, 10 have assigned a buy or strong buy rating, indicating a widespread positive outlook on Arrowhead's growth potential, further bolstering investor confidence.
See More
Arrowhead Pharmaceuticals' Redemplo Receives Positive EMA Recommendation
- EMA Recommendation: Arrowhead Pharmaceuticals' Redemplo received a positive opinion from the European Medicines Agency (EMA) Committee, recommending approval for familial chylomicronemia syndrome, with a final decision from the European Commission expected by Q2 2026, potentially opening new market opportunities for the company.
- Wall Street Optimism: Morgan Stanley upgraded Arrowhead from ‘Equal Weight’ to ‘Overweight’ with a price target increase from $78 to $100, reflecting optimism ahead of late-stage Severe Hypertriglyceridemia (sHTG) data, which is expected to unlock a multibillion-dollar market opportunity.
- Analyst Support: According to Koyfin, 10 out of 12 analysts rated Arrowhead as ‘Buy’ or higher, indicating strong market confidence in its future performance, with an average price target of $84.18, representing a potential upside of 14%.
- Retail Trader Sentiment: On Stocktwits, retail sentiment around ARWR stock surged from ‘bullish’ to ‘extremely bullish’ in the past 24 hours, reflecting investor optimism for the impending drug approval in Europe, with the stock rallying approximately 454% over the past 12 months.
See More
US Stocks Rise on Strong Retail Sales and Earnings Reports
- Strong Retail Sales: US March retail sales rose 1.7% month-over-month, exceeding expectations of 1.4% and marking the largest increase in a year, indicating robust consumer spending that could bolster economic recovery and market confidence.
- Earnings Support: UnitedHealth Group (UNH) reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, raising its full-year forecast to above $18.25, which has driven health insurance stocks higher and reflects industry resilience.
- Fed Nomination in Focus: Kevin Warsh's confirmation hearing before the Senate Banking Committee is drawing attention; despite facing an investigation hurdle, Warsh's commitment to an independent Fed and prioritizing inflation control could influence future monetary policy directions.
- International Tensions Impact Oil Prices: WTI crude oil prices fell over 1% as Iran is set to attend peace talks with the US, while the closure of the Strait of Hormuz threatens to exacerbate the global energy crisis, affecting market sentiment.
See More
U.S. Stocks Mixed as Oil Prices Rebound
- Market Performance: The S&P 500 Index fell by 0.13%, and the Dow Jones Industrial Average also declined by 0.13%, while the Nasdaq 100 saw a slight increase of 0.02%, reflecting market volatility influenced by oil price rebounds and economic data.
- Strong Economic Data: March retail sales rose by 1.7% month-over-month, exceeding expectations of 1.4%, marking the largest increase in a year, indicating robust consumer spending that may support stock prices.
- Oil Price Recovery: WTI crude oil prices rebounded by over 2% as market speculation intensified regarding Iran's participation in upcoming peace talks, potentially exacerbating the global energy crisis.
- Impressive Earnings Reports: UnitedHealth Group reported Q1 adjusted EPS of $9.23, significantly above the consensus of $6.57, leading to a stock price increase of over 7% and raising its full-year earnings forecast, showcasing strong performance in the health insurance sector.
See More
US Stocks Close Lower as Oil Prices Rebound Impact Market
- Market Decline: The S&P 500 index fell by 0.63%, the Dow Jones Industrial Average dropped by 0.59%, and the Nasdaq 100 index decreased by 0.42%, reflecting investor concerns over the uncertainty surrounding Iran's geopolitical situation, which dampened market sentiment.
- Oil Price Rebound Impact: WTI crude oil prices rebounded by over 2% after Iran announced it would not attend peace talks, raising fears of a deepening global energy crisis, which could further hinder economic recovery.
- Supportive Economic Data: March retail sales rose by 1.7% month-over-month, surpassing expectations of 1.4%, indicating robust consumer spending that may provide some support for the stock market, despite overall market pressures.
- Fed Nominee Supports Independence: Fed Chair nominee Kevin Warsh emphasized the importance of monetary policy independence and controlling inflation in his Senate Banking Committee statement, which could positively influence market confidence.
See More
Morgan Stanley Upgrades Arrowhead to Overweight with $100 Target
- Rating Upgrade: Morgan Stanley upgraded Arrowhead Pharmaceuticals (ARWR) from Equal Weight to Overweight and raised its price target from $78 to $100, reflecting expectations of significant catalysts over the next 12 months.
- Clinical Trial Catalyst: Analyst Michael Ulz highlighted that data expected in Q3 2026 from the SHASTA 3 and 4 trials will serve as an important catalyst for Arrowhead, particularly for its lead asset plozasiran targeting severe hypertriglyceridemia.
- Sales Forecast Increase: Ulz anticipates that plozasiran will generate $3.2 billion in adjusted peak sales in severe hypertriglyceridemia, significantly up from his prior forecast of $1.7 billion, indicating strong market confidence in the product.
- Future Catalysts: Over the next 12 months, Arrowhead is also set to release initial results for its Alzheimer’s candidate ARO-MAPT and hyperlipidemia candidate ARO-DIMER-PA, further enhancing investor expectations for its pipeline.
See More
Arrowhead Pharmaceuticals Stock Outlook Optimistic
- Clinical Trial Data Release: Arrowhead Pharmaceuticals is set to release phase three clinical trial data for its RNA interference therapeutic Plozasiran, aimed at treating severe hypertriglyceridemia, in Q3 2026, which is expected to drive stock price increases as the market opportunity remains underappreciated.
- Analyst Rating Upgrade: Morgan Stanley upgraded Arrowhead's stock rating from equal weight to overweight and raised its price target from $78 to $100, implying a 44.4% upside from Monday's close, reflecting strong confidence in the company's future performance.
- Strong Stock Performance: Arrowhead's stock has surged over 473% in the past year, indicating robust market demand for its products and investor confidence, with analysts believing this momentum will continue.
- Market Consensus Support: Among the 13 analysts covering the stock, 10 have assigned a buy or strong buy rating, indicating a widespread positive outlook on Arrowhead's growth potential, further bolstering investor confidence.
See More
